TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Cooperation for Improved Pharmacotherapy in Home-dwelling Elderly People Receiving Polypharmacy - The COOP Study
Brief Summary: Polypharmacy increases the risk of adverse drug effects, interactions and other drug-related problems, and several studies indicate that inappropriate drug use is a major reason for poor health and impaired function in the elderly. A majority of interventions for improvement of drug treatment in the elderly have been evaluated by the use of surrogate outcomes such as drug-related problems, number of prescribed drugs or prevalence of potentially inappropriate prescriptions - and it is so far unclear whether such interventions can result in clinical significant improvements. The primary objective of this trial is therefore to evaluate the effect upon patients, relatives and local health care service of a structured cooperation between a hospital-based geriatrician and family physicians on complex drug regimens in home-dwelling frail elderly patients.


Options:
A: Inclusion Criteria:

* people aged 75 years or older

Exclusion Criteria:

* people aged 75 years or older
* refusal of consent to participate
* a life expectancy of less than 6 months
B: Inclusion Criteria:

* 70 years or more
* Currently receiving eight or more drugs, except ointments and administered via topical nonprescription
* Give their informed written consent to participate in the study.

Exclusion Criteria:

* Estimated life expectancy less than 6 months.
* Active cancer
* Participation in any other clinical trial or program for evaluation of medication in the elderly.
* Institutionalized in nursing homes.
* Surgical intervention scheduled for the next 6 months
C: For interview questionnaire:

Inclusion criteria are:

1. Accepted informed consent,
2. The healthcare professional is practicing in the involved nursing homes.

Exclusion criteria are:

1) Decline/unable to provide consent.

For team-care deprescribing study:

Inclusion criteria are:

1. Accepted informed consent (unless cognitive-impaired, with no or un-contactable next-of-kin),
2. Adult aged 65 years and above,
3. Currently on five or more medications.

Exclusion criteria are:

1. Below the age of 65 years of age,
2. Life expectancy of less than 6 months or respite care.
D: Inclusion Criteria:

* The patient must be on the list of one of the family physicians participating in the study
* Home dwelling (not permanently institutionalised)
* Medications administered by the home nursing service
* Polypharmacy defined as the use of at least seven different systemic medications taken regularly
* Informed consent by the patient or a close relative

Exclusion Criteria:

* Patient or relative denies inclusion
* The family physician does not want the particular patient to participate
* Moderate/severe dementia (Clinical Dementia Rating Scale score \> 1) and contact with the closest proxy less than once every other week.
* The patient does not speak/understand Norwegian
* Expected to become permanently institutionalised within six months
* Life expectancy \< six months

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of Ultrasound Guided Femoral Nerve Blockade and Standard Parenteral Opioid Pain Management Alone in Patients With Hip Fracture in the Emergency Department
Brief Summary: The goal of the study is to evaluate whether pain control achieved by Ultrasound Guided Femoral Nerve Blockade (USFNB) is equal in efficacy to standard pain management practice of parenteral injection of opioid pain medication in patients presenting to the emergency department (ED) with hip fracture.


Options:
A: Inclusion Criteria:

* Patients with femoral neck and intertrochanteric hip fractures
* At least 18 years of age
* Require operative management

Exclusion Criteria:

* Poly-trauma patients
* Pathologic fractures
* Patient who required revision procedures
* Patients with chronic opioid use
* Patients with a clinical status that precludes verbal pain assessment such as dementia, head injuries, and unwillingness to participate.
B: Inclusion Criteria:

* Patients over 18 years of age presenting to the ED with radiographically established intra-, extracapsular hip fracture, able to consent and participate in the study and who have moderate to severe pain (numerical pain score \>= 31) at the time of enrollment.

Exclusion Criteria:

* Patients with a previous history of hypersensitivity to local anesthetics,
* Patients who have signs of a local infection at the site of planned needle placement.
* INR \> 1.4NOAC use within 48 hours
* Prophylactic Low-Molecular Weight Heparin (LMWH) within 12 hours
* Therapeutic LMWH within 24 hours
* Prophylactic Unfractionated Heparin (5000 Units BID or TID) within 6 hours
C: Inclusion Criteria:

* Female ASA physical status 1-3 scheduled for total hip arthroplasty
* Age 18-80 years old
* Able to participate personally or by legal representative in informed consent in English or Spanish

Exclusion Criteria:

* History of relevant drug allergy
* Age less than 18 or greater than 80 years
* Chronic opioid use or drug abuse
* Significant psychiatric disturbance
* Inability to understand the study protocol
* Refusal to provide written consent
D: Inclusion Criteria:

* Adults age greater than or equal to 65 years old with acute hip fracture

Exclusion Criteria:

* ASA greater than or equal to 4
* Open fractures
* Other concomitant injuries that may interfere with positioning or pain scores
* Local anesthetic allergy
* Delirium at the time of consent
* Pre-existing cognitive impairment
* Infection at the site of injection for cFIB
* Previous surgery in femoral triangle
* Warfarin or Anti-Xa inhibitor use
* Long-term opioid use
* Intraoperative complications

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Brief Summary: 24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.


Options:
A: Inclusion Criteria:

* aged 10 to 80
* treatment naive symptomatic PAH
* 6-MWD of 100-425 m
* resting mean pulmonary artery pressure greater than 25 mm Hg, pulmonary capillary wedge pressure less than 15 mm Hg, and pulmonary vascular resistance of 240 dyn.s.cm-5 or greater.

Exclusion Criteria:

* Patients with thromboembolic disease,
* untreated obstructive sleep apnea,
* portal hypertension,
* chronic liver disease or renal insufficiency,
* left-sided or unrepaired congenital heart disease,
* substantial obstructive (FEV1/FVC\<50% predicted) or restrictive (total lung capacity\<60% predicted) lung disease
* Patients receiving phosphodiesterase inhibitors or other prostanoids and endothelin receptor antagonists
B: Inclusion Criteria:

* Written informed consent
* Subject with CTEPH (WHO Group 4) judged as inoperable due to the localization of the obstruction being surgically inaccessible (i.e., distal disease).
* Female of childbearing potential must have a negative pre-treatment serum pregnancy test, be advised on appropriate methods of contraception, and agree to use 2 reliable methods of contraception.

Exclusion Criteria:

* Previous pulmonary endarterectomy.
* Recurrent thromboembolism despite sufficient oral anticoagulants.
* Symptomatic acute pulmonary embolism in the 6-month period prior to randomization.
* Known moderate-to-severe restrictive lung disease (i.e., TLC \< 60% of predicted value) or obstructive lung disease (i.e., FEV1 \< 70% of predicted, with FEV1/FVC \< 65%) or known significant chronic lung disease diagnosed by chest imaging (e.g., interstitial lung disease, emphysema).
* Acute or chronic conditions (other than dyspnea) that limit the ability to comply with study requirements in the 3-month period prior to Screening visit or during the Screening period.
C: Main Inclusion Criteria:

* Male or female of at least 18 years of age
* Confirmed diagnosis of portopulmonary hypertension

Main Exclusion Criteria:

* Severe hepatic impairment
* Severe obstructive or restrictive lung disease
* Pulmonary veno-occlusive disease
* Systolic blood pressure (SBP) \< 90 mmHg at Screening
* ALT/AST \>= 3 x ULN
* Bilirubin \>= 3 mg/dL at Screening
* Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of results
D: Inclusion Criteria:

* PAH NYHA Class II
* Significant elevation of mean pulmonary arterial pressure
* Significant elevation of pulmonary vascular resistance at rest
* Limited 6-minute walk distance

Exclusion Criteria:

* PAH secondary to portal hypertension, complex congenital heart disease or reverse shunt
* Restrictive or obstructive lung disease
* Significant vasoreactivity
* Treatments for PAH (within 4 weeks of randomization)

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: International Register of Open Abdomen
Brief Summary: To evaluate the different indications to Open Abdomen, the different techniques used to perform it, it's management, it's definitive closure and mortality rates linked to the different variables. Moreover to evaluate the 1 month and 1 year follow up in patients underwent to Open Abdomen.


Options:
A: Inclusion Criteria:

* Critically ill/injured requiring intensive care unit admission
* Decision regarding the need to utilize an open abdomen technique after the first laparotomy
* Age \> 18
* Non-pregnant

Exclusion Criteria:

* Decision to formally close the abdomen after the initial laparotomy
* Patients receiving intra-peritoneal chemotherapy
* Pregnancy
* Age \< 18
B: Inclusion Criteria:

* No age limit
* Indication to Open Abdomen
* Informed consent

Exclusion Criteria:

* Informed consent refusal
* No indication to Open Abdomen
C: Inclusion Criteria:

* Open Abdomen

Exclusion Criteria:

* Patients that die in the first 48 hours after the initial intervention
D: Inclusion Criteria:

* Presence of purulent, feculent, or enteric spillage over at least 2 intra-peritoneal quadrants intra-operatively;
* Septic shock, or
* Predisposition-Infection-Response-Organ Dysfunction Score \> 3, or
* World-Society-of-Emergency-Surgery-Sepsis-Severity-Score \> 8

Exclusion Criteria:

* Pregnant;
* Confirmed or strongly suspected severe IAH (IAP\>20 mmHg);
* No intentional of providing ongoing care;
* pancreatitis as the source of peritonitis;
* uncontrolled bleeding

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Incorporating PROMIS Symptom Measures Into Primary Care Practice
Brief Summary: The purpose of this study is to determine the effectiveness of providing PROMIS Profile Scale scores (e.g., sleep, pain, anxiety, depression, energy/fatigue) to physicians on patients' symptoms.


Options:
A: Inclusion Criteria

* Patient must be ≥ 18 years of age.
* Patient must have been seen by a rheumatology health care provider at least two times within the last 18 months at Mayo Clinic Rochester.
* Patient must have rheumatoid arthritis (RA) according to the 2010 ACR/EULAR classification criteria.
* Patient must have the ability to understand and the willingness to sign a written informed consent document.
* Patient must be willing to return to Mayo Clinic Rochester for follow-up appointments and fill out questionnaires as outlined in the study.
B: Inclusion Criteria:

* Age \>18 years
* Diagnosis of gynecologic (ovarian; cervical; uterine; primary peritoneal), lung (non-small cell; small cell), gastrointestinal (colorectal, rectal, gastric, esophageal, GI neuroendocrine, small intestine malignancy, pancreatic, hepatocellular), breast, bladder cancer or prostate malignancy
* Receiving primary medical oncology care at MSKCC medical oncology outpatient clinics
* Receiving cytotoxic chemotherapy not on a clinical trial (or a new hormonal therapy in the case of prostate cancer patients only), with treatment expected to continue for at least four weeks from the time of enrollment
* Signed informed consent and Research Authorization

Exclusion Criteria:

* ECOG performance status greater than 2
* Unable to read and comprehend English language text
C: Inclusion Criteria:

Patients

* Adults ≥ 18 years of age,
* Receiving care from a participating primary care physician
* Report a moderate level of severity ( ≥ 4 on a 0 to 10 scale) on at least one of 5 symptoms (sleep, pain, anxiety, depression, energy/fatigue) based on a 5-item screener.

Physicians

* Primary care physicians within the Indiana University Health and Eskenazi Health systems

Exclusion Criteria:

Patients

* Patients less than 18 years of age
* Patients who do not receive care from a participating primary care physician
* Patients who have less than a moderate level of severity (less than 4 on a 0 to 10 item scale) on each of the 5 symptoms (sleep, pain, anxiety, depression, energy/fatigue) based on a 5-item screener.

Physicians:

* Primary care physicians who do not practice within the Indiana University Health or Eskenazi Health systems
D: Inclusion Criteria:

* General hospital inpatients with risky drinking (AUDIT-C \>= 4/5 (women/men) and AUDIT \< 20)

Exclusion Criteria:

* Patients already recruited during an earlier hospital stay
* Patients physically and mentally not capable of participating in the study
* Patients with a hospital stay of less than 24 hours
* Patients with insufficient language/ reading skills
* Patients employed at one of the departments participating in the study or conducting the study
* Patients with more severe alcohol problems (AUDIT \>= 20)

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Incisional VAC at Cesarean Section for Prevention of Post Operative Wound Complications in the Obese
Brief Summary: To study if incisional vacuum-assisted closure can decrease the risk of infection in cesarean section incisions in the obese compared with standard sterile dressing.


Options:
A: Inclusion Criteria:

* BMI \> 35
* Previous femoral exposure
* Undergoing lower-limb revascularization

Exclusion Criteria:

* Cannot obtain seal
* Non-primary wound closure
* Pre-existing infection
* Endovascular repair
B: Inclusion Criteria:

* Age ≥ 18 years
* Planned elective colorectal resection (those that occur as a scheduled operation in the surgeons' planned operative list)

Exclusion Criteria:

* Palliative colorectal resection where predicted remaining lifespan is likely less than 30 days
* Abdominoperineal resection or pelvic exenteration
* Known allergy/sensitivity to adhesive
* Cases in which there is a suspicion of bowel perforation
* Pregnancy
C: Inclusion Criteria:

* Patients that have undergone cesarean section for delivery; have a BMI greater or equal to 35. All cases of cesarean section including primary and repeat, scheduled and urgent.

Exclusion Criteria:

* Patients who deliver vaginally; age less than 18 years old; silver allergy; non-English speaking
D: Key inclusion criteria BMI greater than or equal to 30 kg/m2 at less than or equal to 22 weeks of gestation Subject is laboring Subject is having an unplanned cesarean section Subject will have Pfannenstiel Skin Incision Subject has the ability to take a picture and email it to a secure account Subject receives prenatal care in the University of Pennsylvania health system and plans to follow up postpartum in the system Subject is greater than or equal to 18 years of age

Key exclusion criteria Subject cannot read or speak English Subject is not 18 years of age Subject does not have ability to send a picture by email Subject has preexisting diabetes mellitus (Type 1 or Type 2) , is using chronic steroids or immune-suppressants, OR being actively treated for a malignancy Subject is undergoing a scheduled cesarean section Subject is allergic to silver

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Incisional VAC at Cesarean Section for Prevention of Post Operative Wound Complications in the Obese
Brief Summary: To study if incisional vacuum-assisted closure can decrease the risk of infection in cesarean section incisions in the obese compared with standard sterile dressing.


Options:
A: Inclusion Criteria:

* All patients undergoing a femoral incision during vascular reconstruction or repair will be considered for study

Exclusion Criteria:

* Emergency procedure
* Unable to give informed consent
B: Inclusion Criteria:

* Written informed consent
* Coronary heart disease patients to transplant more than 2 vascular bridge
* The thigh groin following from the saphenous vein

Exclusion Criteria:

* Subjects does not agree to participate in clinical trials
* Subjects had a injury, operation history of Thigh
* Subjects having ever received chemotherapy before the surgery
* Subjects with known hypersensitivity to components of the surgical sticky membrane
C: Inclusion Criteria:

* Pregnant women with BMI \> 40 undergoing a cesarean delivery at Parkland Health and Hospital System.

Exclusion Criteria:

* Any patient not meeting inclusion criteria will be deemed ineligible.
* All HIV positive patients will be excluded due to the increased risk of infectious complications in these patients.
* Although patients on anticoagulants can use NPWT, they will be excluded as there may be an increased risk of bleeding in these patients.
* according to the wound therapy manufacturer's instructions patients with:

  * fragile skin
  * allergy to silver or acrylic adhesives
  * a malignancy in the wound bed or margins of the wound bed
  * non-enteric and unexplored fistulas
  * necrotic tissue with eschar present
  * exposed arteries, veins, nerves or organs, anastomotic sites, or surgical suction are not candidates for usage of the device.
D: Inclusion Criteria:

* Patients that have undergone cesarean section for delivery; have a BMI greater or equal to 35. All cases of cesarean section including primary and repeat, scheduled and urgent.

Exclusion Criteria:

* Patients who deliver vaginally; age less than 18 years old; silver allergy; non-English speaking

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Incisional VAC at Cesarean Section for Prevention of Post Operative Wound Complications in the Obese
Brief Summary: To study if incisional vacuum-assisted closure can decrease the risk of infection in cesarean section incisions in the obese compared with standard sterile dressing.


Options:
A: Inclusion Criteria:

* Written informed consent
* Post-surgical subcutaneous abdominal wound healing impairment
* Minimum wound size eligible for the application of the randomized treatment- Inclusion, randomization, adequate wound pre-treatment (Debridement) and start of therapy within 48 hours after reopening of the wound, diagnosis for nonclosable wound or in case of spontaneous wound dehiscence

Exclusion Criteria:

* Age \< 18
* Noncompliance with study procedures, visit schedule and follow up
* Pregnancy
* Present or nonclosable defect of the abdominal fascia
* Any pre-existing or ongoing organ system failure, that cannot be stabilized or solved by appropriate medical treatment
* Necrotic tissue with eschar present
* Non-enteric and unexplored fistulas
* Malignancy of the wound
* Use of any other device based on the principle of negative pressure wound therapy on the study wound within ≤ 8 days prior to screening
* Competing therapies or procedures
* Simultaneous participation in other clinical trials
B: Inclusion Criteria:

* Patients aged 18 or older
* Previous colorectal resection with the formation of protective ileostomy due to cancer
* Ileostomy closure surgery as an elective procedure.

Exclusion Criteria:

* Emergency or urgent operation
* Active infection
* Other than ileostomy closure or parastomal hernioplasty operation performed.
* Patents who within 1 week after operation will be re-operated or transferred to Intensive Care Unit or other hospital word due to noninfectious complications
C: Inclusion Criteria:

* All patients over the age of 18 years of age undergoing a laparotomy are eligible for entry into this study. Benign and malignant conditions are eligible for inclusion.

Exclusion Criteria:

* Pregnant patients and those undergoing re-look laparotomies are to be excluded.
D: Inclusion Criteria:

* Patients that have undergone cesarean section for delivery; have a BMI greater or equal to 35. All cases of cesarean section including primary and repeat, scheduled and urgent.

Exclusion Criteria:

* Patients who deliver vaginally; age less than 18 years old; silver allergy; non-English speaking

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Nitrous Oxide for Pain Management of Intrauterine Device Insertion
Brief Summary: The purpose of this study is to determine whether Nitrous Oxide is effective in achieving pain control and satisfaction among nulliparous women getting the intrauterine device (IUD).


Options:
A: Inclusion Criteria:

* Age \>18 OR between the ages of 12-17 with a parent/legal guardian who can consent
* English speaking
* Desires a Mirena® or ParaGard® IUD
* Nulliparous woman
* Can use laughing gas
* Has not taken narcotic pain medications prior to procedure

Exclusion Criteria:

* Currently pregnant
* If you have been pregnant before, pregnancy lasting longer than 19 weeks, 6 days
* Less than 4 weeks have elapsed from the end of a spontaneous abortion or medical abortion.
* Desires Skyla® IUD
* Pelvic Inflammatory Disease in the last 3 months
* Current mucopurulent discharge
* Uterine anomaly that distorts the uterine cavity
* Known uterine fibroid with disruption of the uterine cavity
* Copper allergy/Wilson's disease (for ParaGard®)
* Current cervical or uterine cancer
* Inability to breathe through the nose
* Significant active upper airway infection
B: Inclusion Criteria:

* age 18-45,
* Generally Healthy.
* requesting LNG-IUS for contraception as the primary indication

Exclusion Criteria:

* previous pregnancy beyond 20 weeks,
* previous IUD placement or attempted placement,
* allergy to nitroprusside,
* history of migraines,
* history of heart disease.
C: Inclusion Criteria:

1. plans for IUD insertion for contraception or abnormal uterine bleeding;
2. 18 to 49 years of age;
3. reached more than 6 weeks postpartum or 2 weeks postabortion if recently pregnant;
4. no prior IUD use;
5. not taken analgesics or anxiolytics in the previous 24 hours;
6. not taken misoprostol prior to IUD insertion;
7. the ability and are willing to give informed consent;
8. speaks English or Spanish.

Exclusion Criteria:

1. any contraindication to IUD placement;
2. allergy to lidocaine or sensitivities to components of the lidocaine or placebo gel;
3. chronic narcotic/benzodiazepine/barbiturate use within the past year.
D: Inclusion criteria:

* Nulliparous, as defined in this study as no history of pregnancy ≥ 24 weeks gestational age
* Desires insertion of either levonorgestrel-releasing IUD (LNG-IUD) or copper T380A IUD (Cu-IUD)
* No history of pregnancy in the last 6 weeks
* Able to provide written informed consent in English and comply with all study procedures

Exclusion criteria:

* Known allergy or hypersensitivity to lidocaine or other amino amide local anesthetics
* Prior failed IUD insertion
* Prior IUD use
* Use of narcotic or benzodiazepine medication within the last 24 hours
* U.S. Centers for Disease Control Medical Eligibility Criteria (MEC) category 3 or 4 classification for use of an IUD
* Positive pregnancy test or reasonable risk of pregnancy due to unprotected heterosexual intercourse since the last menstrual period

Answer: A